Edgren Gustaf, Almqvist Rikke, Hartman Mikael, Utter Garth H
*Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden †Department of Epidemiology, Harvard School of Public Health, Boston, MA ‡Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm §Saw Swee Hock School of Public Health, National University of Singapore, Singapore ¶Department of Surgery, National University of Singapore, Singapore; and ‖Department of Surgery, University of California, Davis, Medical Center, Sacramento, CA.
Ann Surg. 2014 Dec;260(6):1081-7. doi: 10.1097/SLA.0000000000000439.
We sought to estimate the long-term risk of sepsis in patients who underwent splenectomy before, during, and after implementation of vaccination.
Because patients who have undergone splenectomy are considered at increased risk of bacterial sepsis, they typically receive vaccination, education, and occasionally antibiotic prophylaxis. However, the extent to which these interventions have actually reduced the risk of sepsis remains unclear.
Retrospective cohort study encompassing all patients in the Swedish national inpatient register, who underwent splenectomy in 1970-2009. Patients were followed for hospitalization for or death from sepsis, as identified using national inpatient and cause of death registers. Relative risks, comparing patients to the background population were expressed as standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs).
Altogether, 20,132 splenectomized patients were included. The overall SIR for hospitalization for sepsis was 5.7 [95% confidence interval (CI), 5.6-6.0]. However, risks depended on the indication for splenectomy, with SIRs varying from 3.4 (95% CI, 3.0-3.8) for trauma patients to 18 (95% CI, 16-19) for patients with hematologic malignancies. SMRs ranged from 3.1 (95% CI, 2.1-4.3) for trauma to 8.7 (95% CI, 6.8-11) for hematologic disease. In regression analyses adjusting for age at splenectomy, follow-up time, sex, and calendar year of splenectomy, there were no significant risk decreases after implementation of routine vaccination, except for in patients with malignant and non-malignant hematologic disease.
The risk of hospitalization or death from sepsis is high in patients who previously underwent splenectomy and depends on the indication for splenectomy. The effectiveness of current vaccination practices warrants further evaluation.
我们试图评估在疫苗接种实施之前、期间及之后接受脾切除术的患者发生败血症的长期风险。
由于接受脾切除术的患者被认为发生细菌性败血症的风险增加,他们通常会接受疫苗接种、教育,偶尔还会接受抗生素预防。然而,这些干预措施实际降低败血症风险的程度仍不清楚。
回顾性队列研究纳入了瑞典国家住院患者登记册中1970年至2009年期间接受脾切除术的所有患者。利用国家住院患者和死亡原因登记册确定患者因败血症住院或死亡情况,并进行随访。将患者与背景人群进行比较的相对风险以标准化发病率比(SIRs)和标准化死亡率比(SMRs)表示。
共纳入20132例接受脾切除术的患者。败血症住院的总体SIR为5.7[95%置信区间(CI),5.6 - 6.0]。然而,风险取决于脾切除术的指征,SIRs范围从创伤患者的3.4(95%CI,3.0 - 3.8)到血液系统恶性肿瘤患者的18(95%CI,16 - 19)。SMRs范围从创伤患者的3.1(95%CI,2.1 - 4.3)到血液系统疾病患者的8.7(95%CI,6.8 - 11)。在对脾切除时的年龄、随访时间、性别和脾切除年份进行校正的回归分析中,除了恶性和非恶性血液系统疾病患者外,常规疫苗接种实施后风险没有显著降低。
既往接受脾切除术的患者发生败血症住院或死亡的风险很高,且取决于脾切除术的指征。当前疫苗接种措施的有效性值得进一步评估。